Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis-Reference-Cited by-同舟云学术

Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis

Published:2017-08 Issue:1 Volume:47 Page:108-114
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Iannone Florenzo,Santo Leonardo,Anelli Maria Grazia,Bucci Romano,Semeraro Angelo,Quarta Laura,D’Onofrio Francesca,Marsico Antonio,Carlino Giorgio,Casilli Oriana,Cacciapaglia Fabio,Zuccaro Carmelo,Falappone Paola Chiara,Cantatore Francesco Paolo,Muratore Maurizio,Lapadula Giovanni

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference28 articles.

1. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials;Zink;Arthritis Rheum,2006

2. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors;Iannone;J Rheumatol,2012

3. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab;Neovius;Ann Rheum Dis,2015

4. Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings;Iannone;J Rheumatol,2016

5. Lie E, Kristensen LE, Forsblad-d’Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT, et al. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis 2015;74:970-8.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study;International Journal of Rheumatic Diseases;2024-03

2. Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network;Scientific Reports;2024-01-16

3. Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study;Rheumatology International;2023-10-10

4. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries;Rheumatology;2023-06-14

5. Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs;PLOS Computational Biology;2023-06-02